R&G PharmaStudies Co., Ltd.

SZSE:301333 Stock Report

Market Cap: CN¥5.0b

R&G PharmaStudies Past Earnings Performance

Past criteria checks 2/6

R&G PharmaStudies has been growing earnings at an average annual rate of 13.2%, while the Life Sciences industry saw earnings growing at 17.2% annually. Revenues have been growing at an average rate of 10.6% per year. R&G PharmaStudies's return on equity is 6.8%, and it has net margins of 16%.

Key information

13.2%

Earnings growth rate

10.0%

EPS growth rate

Life Sciences Industry Growth26.8%
Revenue growth rate10.6%
Return on equity6.8%
Net Margin16.0%
Last Earnings Update30 Sep 2024

Recent past performance updates

R&G PharmaStudies' (SZSE:301333) Conservative Accounting Might Explain Soft Earnings

Nov 06
R&G PharmaStudies' (SZSE:301333) Conservative Accounting Might Explain Soft Earnings

Shareholders Will Be Pleased With The Quality of R&G PharmaStudies' (SZSE:301333) Earnings

Apr 29
Shareholders Will Be Pleased With The Quality of R&G PharmaStudies' (SZSE:301333) Earnings

Recent updates

R&G PharmaStudies' (SZSE:301333) Conservative Accounting Might Explain Soft Earnings

Nov 06
R&G PharmaStudies' (SZSE:301333) Conservative Accounting Might Explain Soft Earnings

R&G PharmaStudies' (SZSE:301333) Dividend Will Be Reduced To CN¥0.20

Jul 01
R&G PharmaStudies' (SZSE:301333) Dividend Will Be Reduced To CN¥0.20

Is There An Opportunity With R&G PharmaStudies Co., Ltd.'s (SZSE:301333) 27% Undervaluation?

Jun 06
Is There An Opportunity With R&G PharmaStudies Co., Ltd.'s (SZSE:301333) 27% Undervaluation?

Shareholders Will Be Pleased With The Quality of R&G PharmaStudies' (SZSE:301333) Earnings

Apr 29
Shareholders Will Be Pleased With The Quality of R&G PharmaStudies' (SZSE:301333) Earnings

Revenue & Expenses Breakdown

How R&G PharmaStudies makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

SZSE:301333 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2475912113656
30 Jun 2473813512655
31 Mar 2473815710953
31 Dec 237211639953
30 Sep 236941558253
30 Jun 236731388552
31 Mar 236281158051
01 Jan 236381137950
30 Sep 226341127648
30 Jun 226401107746
31 Mar 226321018144
01 Jan 22608997941
31 Dec 20484846535
31 Dec 19425835731
31 Dec 1514224350
31 Dec 149614280
31 Dec 137812190

Quality Earnings: 301333 has high quality earnings.

Growing Profit Margin: 301333's current net profit margins (16%) are lower than last year (22.4%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 301333's earnings have grown by 13.2% per year over the past 5 years.

Accelerating Growth: 301333's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 301333 had negative earnings growth (-22.1%) over the past year, making it difficult to compare to the Life Sciences industry average (-14.4%).


Return on Equity

High ROE: 301333's Return on Equity (6.8%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 19:35
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

R&G PharmaStudies Co., Ltd. is covered by 4 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Hao WuChasing Securities
Jin ZhangChina International Capital Corporation Limited
Shitong HanCitic Securities Co., Ltd.